Comparison Between Dexamethasone and Prednisolone in Acute Respiratory Distress Syndrome (ARDS) Patients: A Literature Review
DOI:
https://doi.org/10.53089/medula.v14i8.1275Keywords:
ARDS, acute respiratory distress syndorme, dexamthasone, prednisoloneAbstract
During the COVID-19 pandemic, dexamethasone and methylprednisolone are used to treat COVID-19 patients, particularly those who have acute respiratory distress syndrome (ARDS). Numerous studies have demonstrated that dexamethasone significantly improves respiratory function and lowers mortality in COVID-19 patients, particularly those who need mechanical ventilation. Patients with ARDS with COVID-19 who received dexamethasone had fewer days alive and ventilator-free days, according to a randomized study like the CoDEX trial. But methylprednisolone has also demonstrated encouraging outcomes in treating severe COVID-19 pneumonia, particularly when used as a short-term treatment. The dosage and mode of administration of the two medications differ; dexamethasone is more frequently used to treat the systemic inflammation brought on by this viral infection.
References
Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239–42.
Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. Jama. 2020;324(13):1307–16.
Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19—preliminary report. N Engl J Med. 2020;383(19):1813–36.
Dequin P-F, Heming N, Meziani F, Plantefève G, Voiriot G, Badié J, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324(13):1298–306.
Guillon A, Hiemstra P, Si-Tahar M. Pulmonary immune responses against SARS-CoV-2 infection: harmful or not? Intensive Care Med. 2020;46(10):1897–900.
Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020;368(6490):473–4.
Sinha P, Matthay M, Calfee C. Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152–4.
Yang X, Yu Y, Xu J, Shu H, Liu H, Wu Y, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475–81.
Wang X, Du Z, Huang G, Pasco RF, Fox SJ, Galvani AP, et al. Effects of cocooning on coronavirus disease rates after relaxing social distancing. Emerg Infect Dis. 2020;26(12):3066–8.
Singanayagam A, Glanville N, Girkin JL, Ching YM, Marcellini A, Porter JD, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads and mucus production in COPD exacerbations. Nat Commun. 2018;9(1):2229.
Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, Linsell L. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2020;384(8):693–704.
Group TRC. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020;384(8):693–704.
Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, placebo-controlled trial. Clin Infect Dis. 2021;72(9):e373–81.
Doosti-Irani A, Nazemipour M, Mansournia MA. What are network meta-analyses (NMAs)? A primer with four tips for clinicians who read NMAs and who perform them (methods matter series). Br J Sports Med. 2020;55:520–1.
Leucht S, Chaimani A, Cipriani AS, Davis JM, Furukawa TA, Salanti G. Network meta-analyses should be the highest level of evidence in treatment guidelines. Eur Arch Psychiatry Clin Neurosci. 2016;266(6):477–80.
Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Assessing risk of bias in a randomized trial. In: Cochrane handbook for systematic reviews of interventions; 2019. p. 205–28.
Veroniki AA, Vasiliadis HS, Higgins JP, Salanti G. Evaluation of inconsistency in networks of interventions. Int J Epidemiol. 2013;42(1):332–45.
Mansournia MA, Collins GS, Nielsen RO. A CHecklist for statistical assessment of medical papers (the CHAMP statement): explanation and elaboration. Br J Sports Med. 2021;55(18):1009–17.
Chaimani A, Higgins JP, Mavridis D, Spyridonos P, Salanti G. Graphical tools for network meta-analysis in STATA. PloS One. 2013;8(10):e76654.
Balduzzi S, Rücker G, Nikolakopoulou A, Papakonstantinou T, Salanti G, Efthimiou O, et al. Netmeta: an R package for network meta-analysis using frequentist methods. J Stat Softw. 2023;106(2):1–40.
Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58.
Edalatifard M, Akhtari M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalized severe COVID-19 patients: results from a randomized controlled clinical trial. Eur Respir J. 2020;56(6).
Jamaati H, Hashemian SM, Farzanegan B, Malekmohammad M, Tabarsi P, Marjani M, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947.
Corral-Gudino L, Bahamonde A, Arnaiz-Revillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr. 2021;133(7–8):303–11.
Ranjbar K, Moghadami M, Mirahmadizadeh A, Fallahi MJ, Khaloo V, Shahriarirad R, et al. Methylprednisolone or dexamethasone, which one is superior corticosteroid in the treatment of hospitalized COVID-19 patients: a triple-blinded randomized controlled trial. BMC Infect Dis. 2021;21(1):337.
Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–29.
Ghanei M, Solaymani-Dodaran M, Qazvini A, Ghazale AH, Setarehdan SA, Saadat SH, et al. The efficacy of corticosteroids therapy in patients with moderate to severe SARS-CoV-2 infection: a multicenter, randomized, open-label trial. Respir Res. 2021;22(1):245.
Maskin LP. High- versus low-dose dexamethasone for the treatment of COVID-19-related acute respiratory distress syndrome: a multicenter, randomized open-label clinical trial. J Intensive Care Med. 2022;37(4):491–9.
Yu LM, Bafadhel M, Dorward J, Hayward G, Saville BR, Gbinigie O, et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. Lancet. 2021;398(10303):843–55.
Braude AC, Rebuck AS. Prednisone and methylprednisolone disposition in the lung. Lancet. 1983;2(8357):995–7.
Greos LS, Vichyanond P, Bloedow DC, Irvin CG, Larsen GL, Szefler SJ, et al. Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis. The American review of respiratory disease, 144(3 Pt 1), 586–592
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Medical Profession Journal of Lampung
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
